Results 131 to 140 of about 5,735,852 (363)

#VaccinesWork… don't they?

open access: yesThe Lancet Global Health, 2018
The Lancet Global Health
doaj   +1 more source

Global health degrees: at what cost? [PDF]

open access: gold, 2020
Anita Svadzian   +3 more
openalex   +1 more source

Global Health [PDF]

open access: yesRevista Latino-Americana de Enfermagem, 2014
openaire   +4 more sources

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

Surprise us, Mr Trump

open access: yesThe Lancet Global Health, 2017
The Lancet Global Health
doaj   +1 more source

Exploring equity in global health collaborations: a qualitative study of donor and recipient power dynamics in Liberia [PDF]

open access: gold
Brigid E. Cakouros   +6 more
openalex   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Pragmatic global health

open access: yesThe Lancet Global Health, 2023
The Lancet Global Health
doaj   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy